8-HETEROCYCLIC-3-(PHENYLSULFONYL)-[1,2,3]TRIAZOLO[1,5A]QUINAZOLIN-5(4H)-ONE DERIVATIVES AS ANTI-BACTERIALS

Title:

8-HETEROCYCLIC-3-(PHENYLSULFONYL)-[1,2,3]TRIAZOLO[1,5A]QUINAZOLIN-5(4H)-ONE DERIVATIVES AS ANTI-BACTERIALS

Document Type and Number:

WIPO Patent Application WO/2024/002934

Kind Code:

A1

Abstract:

The present invention relates to 8-heterocyclic-3-(phenylsulfonyl)-[1,2,3] triazolo[1,5a]quinazolin-5(4H)-one derivatives and pharmaceutical compositions thereof as well as to their uses in methods of reducing the virulence of bacteria (preferably Staphylococcus aureus) that express accessory gene regulator A (AgrA) or an ortholog of AgrA; in methods of inhibition of the quorum sensing in bacteria, preferably in S. aureus; and in methods for preventing or treating diseases caused or exacerbated by bacteria, preferably by S. aureus, such as skin or lung infections, atopic dermatitis, Netherton syndrome or psoriasis in a subject. The compounds exhibited superior ability to inhibit the transcription of genes under the control of the P3 promoter in S. aureus even in the presence of human serum or human serum albumin.

More Like This:

JP4537576	Arylphenyl-substituted cyclic keto-enols
JP6027547	(1, 2, 4) 4 and 3-triazolo [A] quinoxaline derivative as a prevention medicine of Hosuhoji esterase
JP2892772	[Title of Invention] A method for producing an acid amide compound having a pyrazoloazole skeleton or a pyrazolone skeleton.

Inventors:

BOUROTTE MARILYNE (FR)
DALE GLENN E (CH)
DEFERT OLIVIER (FR)
GITZINGER MARC (CH)
LOCIURO SERGIO (CH)
MICHELOTTI ALESSIA (FR)
TRAUNER ANDREJ (CH)
TREBOSC VINCENT (FR)

Application Number:

PCT/EP2023/067241

Publication Date:

January 04, 2024

Filing Date:

June 26, 2023

Export Citation:

Click for automatic bibliography generation Help

Assignee:

BIOVERSYS AG (CH)

International Classes:

C07D487/04; A61P31/04; C07D519/00

Domestic Patent References:

WO2020109350A1	2020-06-04
WO2009151561A2	2009-12-17
WO2020109350A1	2020-06-04

Other References:

LEE AS ET AL., NAT. REV. DIS. PRIMERS, vol. 4, 2018, pages 1 - 23
GEOGHEGAN JA ET AL., TRENDS MICROBIOL, vol. 26, no. 6, 2018, pages 484 - 497
WILLIAMS MR ET AL., CELL REPORTS, vol. 30, no. 9, 2020, pages 2923 - 2933
DICKEY SW ET AL., NAT. REV. DRUG DISCOV., vol. 16, no. 7, 2017, pages 457 - 471
MUHLEN, SDERSCH, P, CURR. TOP. MICROBIOL. IMMUNOL., vol. 398, 2016, pages 147 - 183
KHAN, BA ET AL., EXPERT OPIN. INVESTIG. DRUGS, vol. 24, no. 5, 2015, pages 689 - 704
OLIVEIRA D ET AL., TOXINS, vol. 10, 2018, pages 252
GORDON CP ET AL., J. MED. CHEM., vol. 56, no. 4, 2013, pages 1389 - 404
SULLY EK ET AL., PLOSPATHOG., vol. 10, no. 6, 2014, pages e1004174
DICKEY SW ET AL., NAT REV DRUG DISCOV, vol. 16, no. 7, 2017, pages 457 - 471

Attorney, Agent or Firm:

SPERRLE, Martin (CH)

Download PDF:

View/Download PDF PDF Help

Claims:

CLAIMS

1. A compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, or tautomer thereof: Formula (I) wherein:

R¹ is independently selected from -H, halogen, -Ci-Ce alkyl, and -Ci-Ce alkoxy, wherein said alkyl and alkoxy is each optionally substituted with one or more R¹¹;

R³ is independently selected from -H, -Ci-Ce alkyl, and -Ci-Ce alkoxy, wherein said alkyl and alkoxy is each optionally substituted by one or more R¹¹;

R⁷ is independently selected from -H and -OH;

R⁸ is a group of the Formula (A): Formula (A) wherein n is independently an integer from 0 to 3; m is independently an integer from 0 to 3;

Y¹ is independently, at each occurrence, selected from CR⁸¹R⁸², C(O), and O;

Y² is independently, at each occurrence, selected from CR^81AR^82A, and O;

Y³ is independently selected from CR⁸⁴R⁸⁵; CHR⁸⁶; NR⁸⁷, and O; wherein the sum of m and n is at least 2 when Y³ is CR⁸⁴R⁸⁵ and wherein the sum of m and n is at least 3 when Y³ is CHR⁸⁶, NR⁸⁷, or O;

R⁸¹, R⁸², R^81A and R^82A are independently, at each occurrence, selected from -H and - Ci-Ce alkyl, or one of R⁸¹ and R^81A, together with the carbon atoms to which they are attached, can combine to form a bridging ethylene;

R⁸⁴ and R⁸⁵, together with the carbon atom to which they are attached, combine to form a -C4-C7 cycloalkyl or a 4- to 7- membered heterocycle, wherein said cycloalkyl and heterocycle is each optionally substituted with one or more halogen, -Ci-Ce alkyl, -Ci-Ce haloalkyl, or -OH;

R⁸⁶ is independently selected from -H, -COOH, and -NR⁸⁸R⁸⁹; or R⁸⁶, together with the carbon atom to which it is attached, can combine with one of R⁸¹, R^81A, R⁸² or R^82A and the carbon atoms to which they are attached to form a 5- to 6-membered heterocycle, wherein said heterocycle is optionally substituted with one or more halogen, -Ci-Ce alkyl, -Ci-Ce haloalkyl, -OH, or -COOH;

R⁸⁸ and R⁸⁹ are independently, at each occurrence, selected from -H and -Ci-Ce alkyl, or one of R⁸⁸ or R⁸⁹, together with the nitrogen atom to which they are attached, can combine with one of R⁸¹, R^81A, R⁸² or R^82A and the carbon atoms to which they are attached to form a 5- to 6-membered heterocycle;

R⁸⁷ is independently selected from -H, -Ci-Ce alkyl, -C(O)Ci-Ce alkyl, -S(O)2NH2, - S(O)2Ci-Ce alkyl, -Cs-Ce cycloalkyl, and 4- to 6-membered heterocycle; wherein each alkyl is optionally substituted with one or more halogen, -Ci-Ce alkoxy, -OH, -O(CH2)2-OH, -NH2, - NHCi-Ce alkyl, or N(Ci-Ce alkyl)2; wherein said cycloalkyl is optionally substituted with one or more halogen, -Ci-Ce alkyl, -Ci-Ce haloalkyl, or -OH; wherein said heterocycle is optionally substituted with one or more halogen, -Ci-Ce alkyl, -Ci-Ce haloalkyl, or -OH; or R⁸⁷, together with the nitrogen atom to which it is attached, can combine with one of R⁸¹, R^81A, R⁸² or R^82A and the carbon atoms to which they are attached to form a 5- to 6- membered heterocycle or 5- to 6-membered heteroaryl, wherein said heterocycle or heteroaryl is each optionally substituted with one or more halogen, -Ci-Ce alkyl, -Ci-Ce haloalkyl, or -OH; and

R¹¹ is independently, at each occurrence, halogen or -OH.

2. The compound of claim 1, wherein R¹ is -CH3.

3. The compound of any of the preceding claims, wherein R³ is -CH3.

4. The compound of any of the preceding claims, wherein R⁷ is -H.

5. The compound of any of the preceding claims, wherein R⁷ is -OH.

6. The compound of any of the preceding claims, wherein Y³ is CR⁸⁴R⁸⁵.

7. The compound of any of claims 1 to 5, wherein Y³ is CHR .

8. The compound of any of claims 1 to 5, wherein Y³ is NR⁸⁷.

9. The compound of claim 8, wherein R⁸⁷ is independently selected from -H, -Ci-Ce alkyl, -C(O)Ci-Ce alkyl, -S(O)2NH2, -S(O)2Ci-Ce alkyl, -Cs-Ce cycloalkyl, and 4- to 6-membered heterocycle; wherein each alkyl is optionally substituted with one or more halogen, -Ci-Ce alkoxy, -OH, -O(CH2)2-OH, -NH2, -NHCi-Ce alkyl, orN(Ci-Ce alkyl)2; wherein said cycloalkyl is optionally substituted with one or more halogen, -Ci-Ce alkyl, -Ci-Ce haloalkyl, or -OH; and wherein said heterocycle is optionally substituted with one or more halogen, -Ci-Ce alkyl, -Ci- Ce haloalkyl, or -OH.

10. The compound of claim 1, wherein R⁸ comprises the Formula (B): Formula (B) wherein:

R⁸¹ is independently, at each occurrence, selected from -H and -C1-C2 alkyl;

R⁸⁷ is independently selected from -H, -C1-C2 alkyl, and 4- to 6-membered heterocycle, preferably wherein said heterocycle comprises one heteroatom selected from O and N; and p is 0, 1 or 2.

11. The compound of claim 1 , wherein R⁸ comprises the Formula (C): Formula (C) wherein:

Y⁴ is selected from -CR⁹¹R⁹²-, -NR⁹³-, and O;

R⁹¹ and R⁹² are each independently selected from -H, -Ci-Ce alkyl, and -OH; and R⁹³ is selected from -H and -Ci-Ce alkyl. 12. The compound of claim 1, wherein said compound is selected from:

3-(2,4-dimethylbenzenesulfonyl)-7-hydroxy-8-(4-methylpiperazin-l-yl)-4H,5H-

[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 1);

3-(2,4-dimethylbenzenesulfonyl)-7-hydroxy-8-{6-methyl-2,6-diazaspiro[3.3]heptan-2- yl}-4H,5H-[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 2);

3-(2,4-dimethylbenzenesulfonyl)-8-{8-methyl-2,8-diazaspiro[4.5]decan-2-yl}-lH,5H-

[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 3);

3-(2,4-dimethylbenzenesulfonyl)-8-{2-methyl-2,9-diazaspiro[5.5]undecan-9-yl}- lH,5H-[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 4);

3-(2,4-dimethylbenzenesulfonyl)-8-{9-methyl-2,9-diazaspiro[5.5]undecan-2-yl}- lH,5H-[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 5);

3-(2,4-dimethylbenzenesulfonyl)-8-{9-methyl-3,9-diazaspiro[5.5]undecan-3-yl}- lH,5H-[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 6);

3-(2,4-dimethylbenzenesulfonyl)-8-{6-oxa-2,9-diazaspiro[4.5]decan-2-yl}-4H,5H-

[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 7);

3-(2,4-dimethylbenzenesulfonyl)-8-{9-methyl-6-oxa-2,9-diazaspiro[4.5]decan-2-yl}- 4H,5H-[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 8);

3-(2,4-dimethylbenzenesulfonyl)-8-{5-oxa-2,8-diazaspiro[3.5]nonan-8-yl}-4H,5H-

[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 9);

3-(2,4-dimethylbenzenesulfonyl)-8-{2-methyl-5-oxa-2,8-diazaspiro[3.5]nonan-8-yl}- 4H,5H-[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 10);

3 -(2,4-dimethylbenzenesulfonyl)-8- {6-methyl- 1 ,6-diazaspiro[3.3]heptan- 1 -yl} - 4H,5H-[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 11);

3-(2,4-dimethylbenzenesulfonyl)-8-{l-methyl-l,6-diazaspiro[3.3]heptan-6-yl}- 4H,5H-[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 12);

3-(2,4-dimethylbenzenesulfonyl)-8-{2-oxa-6-azaspiro[3.3]heptan-6-yl}-4H,5H-

[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 13);

3-(2,4-dimethylbenzenesulfonyl)-8-{6-methyl-2,6-diazaspiro[3.3]heptan-2-yl}- 4H,5H-[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 14);

3-(2,4-dimethylbenzenesulfonyl)-8-{l-oxa-4,9-diazaspiro[5.5]undecan-9-yl}-lH,5H-

[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 15);

3-(2,4-dimethylbenzenesulfonyl)-8-{4-methyl-l-oxa-4,9-diazaspiro[5.5]undecan-9- yl}-lH,5H-[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 16);

3-(2,4-dimethylbenzenesulfonyl)-8-{l-oxa-4,9-diazaspiro[5.5]undecan-4-yl}-lH,5H-

[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 17);

3-(2,4-dimethylbenzenesulfonyl)-8-{9-methyl-l-oxa-4,9-diazaspiro[5.5]undecan-4- yl}-lH,5H-[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 18);

3-(2,4-dimethylbenzenesulfonyl)-8-[(7R)-7-hydroxy-3,9-diazaspiro[5.5]undecan-3- yl]-lH,5H-[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 19);

3-(2,4-dimethylbenzenesulfonyl)-8-{6-hydroxy-2-azaspiro[3.3]heptan-2-yl}-lH,5H-

[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 20);

3-(2,4-dimethylbenzenesulfonyl)-8-{6-hydroxy-6-methyl-2-azaspiro[3.3]heptan-2-yl}- lH,5H-[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 21);

3-(2,4-dimethylbenzenesulfonyl)-8-(4-methylpiperazin-l-yl)-4H,5H-

[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 22);

3-(2,4-dimethylbenzenesulfonyl)-8-(piperazin-l-yl)-4H,5H-[l,2,3]triazolo[l,5- a]quinazolin-5-one (Compound 23);

3-(2,4-dimethylbenzenesulfonyl)-8-[(3R,5S)-3,5-dimethylpiperazin-l-yl]-4H,5H-

[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 24); rac-3-(2,4-dimethylbenzenesulfonyl)-8-[(3R,5S)-3,4,5-trimethylpiperazin-l-yl]- 4H,5H-[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 25);

3-(2,4-dimethylbenzenesulfonyl)-8-(3,5-dimethylpiperazin-l-yl)-4H,5H-

[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 26);

3-(2,4-dimethylbenzenesulfonyl)-8-(3,4,5-trimethylpiperazin-l-yl)-4H,5H-

[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 27); rac-3-(2,4-dimethylbenzenesulfonyl)-8-[(2R,5S)-2,5-dimethylpiperazin-l-yl]-4H,5H-

[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 28);

3-(2,4-dimethylbenzenesulfonyl)-8-(3,3,4-trimethylpiperazin-l-yl)-4H,5H-

[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 29);

3-(2,4-dimethylbenzenesulfonyl)-8-{octahydropyrazino[2,l-c][l,4]oxazin-8-yl}- 4H,5H-[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 30);

3-(2,4-dimethylbenzenesulfonyl)-8-[4-(methylamino)piperidin-l-yl]-4H,5H-

[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 31);

8-[4-(dimethylamino)piperidin-l-yl]-3-(2,4-dimethylbenzenesulfonyl)-4H,5H-

[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 32); 8-(4-aminopiperidin-l-yl)-3-(2,4-dimethylbenzenesulfonyl)-4H,5H-

[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 33);

3-(2,4-dimethylbenzenesulfonyl)-8-[3-(methylamino)pyrrolidin-l-yl]-4H,5H-

[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 34);

8-[(3R)-3-aminopyrrolidin-l-yl]-3-(2,4-dimethylbenzenesulfonyl)-4H,5H-

[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 35);

3-(2,4-dimethylbenzenesulfonyl)-8-{octahydropyrrolo[l,2-a]pyrazin-2-yl}-4H,5H-

[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 36);

8-[(8aS)-octahydropyrrolo[l,2-a]pyrazin-2-yl]-3-(2,4-dimethylbenzenesulfonyl)- 4H,5H-[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 37);

8-[(8aR)-octahydropyrrolo[l,2-a]pyrazin-2-yl]-3-(2,4-dimethylbenzenesulfonyl)- 4H,5H-[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 38);

3-(2,4-dimethylbenzenesulfonyl)-8-{l-methyl-octahydro-lH-pyrrolo[3,2-c]pyri din-5- yl}-4H,5H-[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 39);

8-[(3aR,6aS)-octahydropyrrolo[3,4-c]pyrrol-2-yl]-3-(2,4-dimethylbenzenesulfonyl)- 4H,5H-[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 40);

8-(4-tert-butylpiperazin-l-yl)-3-(2,4-dimethylbenzenesulfonyl)-4H,5H-

[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 41);

3-(2,4-dimethylbenzenesulfonyl)-8-[4-(2-methoxyethyl)piperazin-l-yl]-4H,5H-

[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 42);

3-(2,4-dimethylbenzenesulfonyl)-8-[4-(2-hydroxyethyl)piperazin-l-yl]-4H,5H-

[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 43);

3-(2,4-dimethylbenzenesulfonyl)-8-[4-(l-hydroxypropan-2-yl)piperazin-l-yl]-4H,5H-

[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 44);

3-(2,4-dimethylbenzenesulfonyl)-8-{4-[2-(2-hydroxyethoxy)ethyl]piperazin-l-yl}- 4H,5H-[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 45);

3-(2,4-dimethylbenzenesulfonyl)-8-[4-(2-hydroxyethyl)-l,4-diazepan-l-yl]-4H,5H-

[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 46);

8-(l,4-diazepan-l-yl)-3-(2,4-dimethylbenzenesulfonyl)-4H,5H-[l,2,3]triazolo[l,5- a]quinazolin-5-one (Compound 47);

3-(2,4-dimethylbenzenesulfonyl)-8-(l,4-oxazepan-4-yl)-4H,5H-[l,2,3]triazolo[l,5- a]quinazolin-5-one (Compound 48);

3-(2,4-dimethylbenzenesulfonyl)-8-(4-methyl-l,4-diazepan-l-yl)-4H,5H- [l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 49);

8-{[(lR,3R,5S)-8-azabicyclo[3.2.1]octan-3-yl]amino}-3-(2,4- dimethylbenzenesulfonyl)-lH,5H-[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 50);

3-(2,4-dimethylbenzenesulfonyl)-8-[4-(2,2,2-trifluoroethyl)piperazin-l-yl]-4H,5H- [ 1 ,2,3]triazolo[ 1 ,5-a]quinazolin-5 -one(Compound 51);

3-(2,4-dimethylbenzenesulfonyl)-8-[4-(2-methylpropanoyl)piperazin-l-yl]-4H,5H-

[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 52);

4-[3-(2,4-dimethylbenzenesulfonyl)-5-oxo-4H,5H-[l,2,3]triazolo[l,5-a]quinazolin-8- yl]-l-methylpiperazin-2-one (Compound 53);

3-(2,4-dimethylbenzenesulfonyl)-8-{5H,6H,7H,8H-imidazo[l,2-a]pyrazin-7-yl}- 4H,5H-[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 54);

3-(2,4-dimethylbenzenesulfonyl)-8-[4-(oxetan-3-yl)piperazin-l-yl]-4H,5H-

[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 55);

3-(2,4-dimethylbenzenesulfonyl)-8-[4-(oxan-4-yl)piperazin-l-yl]-lH,5H-

[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 56);

8-[4-(2-aminoethyl)piperazin-l-yl]-3-(2,4-dimethylbenzenesulfonyl)-4H,5H-

[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 57);

8-{4-[3-(diethylamino)propanoyl]piperazin-l-yl}-3-(2,4-dimethylbenzenesulfonyl)- 4H,5H-[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 58);

3-(2,4-dimethylbenzenesulfonyl)-8-[4-(l-methylpiperidin-4-yl)piperazin-l-yl]-lH,5H-

[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 59);

8-(4-cyclopropylpiperazin-l-yl)-3-(2,4-dimethylbenzenesulfonyl)-4H,5H-

[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 60);

3-(2,4-dimethylbenzenesulfonyl)-8-(4-methanesulfonylpiperazin-l-yl)-4H,5H-

[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 61);

4-[3-(2,4-dimethylbenzenesulfonyl)-5-oxo-4H,5H-[l,2,3]triazolo[l,5-a]quinazolin-8- yl]piperazine-l -sulfonamide (Compound 62); and

2-[3-(2,4-Dimethyl-benzenesulfonyl)-5-oxo-4,5-dihydro-[l,2,3]triazolo[l,5- a]quinazolin-8-yl]-2-aza-spiro[3.3]heptane-6-carboxylic acid (Compound 63); and l-[3-(2,4-Dimethyl-benzenesulfonyl)-5-oxo-4,5-dihydro-[l,2,3]triazolo[l,5- a]quinazolin-8-yl]-piperidine-4-carboxylic acid (Compound 64); or a pharmaceutically acceptable salt thereof.

13. The compound of claim 1, wherein said compound is selected from:

3-(2,4-dimethylbenzenesulfonyl)-7-hydroxy-8-(4-methylpiperazin-l-yl)-4H,5H-

[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 1);

3-(2,4-dimethylbenzenesulfonyl)-7-hydroxy-8-{6-methyl-2,6-diazaspiro[3.3]heptan-2- yl}-4H,5H-[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 2);

3-(2,4-dimethylbenzenesulfonyl)-8-{8-methyl-2,8-diazaspiro[4.5]decan-2-yl}-lH,5H-

[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 3);

3-(2,4-dimethylbenzenesulfonyl)-8-{6-oxa-2,9-diazaspiro[4.5]decan-2-yl}-4H,5H-

[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 7);

3-(2,4-dimethylbenzenesulfonyl)-8-{9-methyl-6-oxa-2,9-diazaspiro[4.5]decan-2-yl}- 4H,5H-[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 8);

3-(2,4-dimethylbenzenesulfonyl)-8-{l-methyl-l,6-diazaspiro[3.3]heptan-6-yl}- 4H,5H-[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 12);

3-(2,4-dimethylbenzenesulfonyl)-8-{6-methyl-2,6-diazaspiro[3.3]heptan-2-yl}- 4H,5H-[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 14);

3-(2,4-dimethylbenzenesulfonyl)-8-{4-methyl-l-oxa-4,9-diazaspiro[5.5]undecan-9- yl}-lH,5H-[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 16);

3-(2,4-dimethylbenzenesulfonyl)-8-{6-hydroxy-6-methyl-2-azaspiro[3.3]heptan-2-yl}- lH,5H-[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 21);

3-(2,4-dimethylbenzenesulfonyl)-8-(4-methylpiperazin-l-yl)-4H,5H-

[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 22);

3-(2,4-dimethylbenzenesulfonyl)-8-(piperazin-l-yl)-4H,5H-[l,2,3]triazolo[l,5- a]quinazolin-5-one (Compound 23);

3-(2,4-dimethylbenzenesulfonyl)-8-[(3R,5S)-3,5-dimethylpiperazin-l-yl]-4H,5H-

[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 24); rac-3-(2,4-dimethylbenzenesulfonyl)-8-[(3R,5S)-3,4,5-trimethylpiperazin-l-yl]- 4H,5H-[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 25); rac-3-(2,4-dimethylbenzenesulfonyl)-8-[(2R,5S)-2,5-dimethylpiperazin-l-yl]-4H,5H-

[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 28);

3-(2,4-dimethylbenzenesulfonyl)-8-[4-(methylamino)piperidin-l-yl]-4H,5H-

[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 31);

3-(2,4-dimethylbenzenesulfonyl)-8-{octahydropyrrolo[l,2-a]pyrazin-2-yl}-4H,5H-

[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 36); 3-(2,4-dimethylbenzenesulfonyl)-8-{l-methyl-octahydro-lH-pyrrolo[3,2-c]pyridin-5- yl}-4H,5H-[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 39);

3-(2,4-dimethylbenzenesulfonyl)-8-{4-[2-(2-hydroxyethoxy)ethyl]piperazin-l-yl}- 4H,5H-[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 45);

3-(2,4-dimethylbenzenesulfonyl)-8-[4-(2-hydroxyethyl)-l,4-diazepan-l-yl]-4H,5H-

[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 46);

8-(l,4-diazepan-l-yl)-3-(2,4-dimethylbenzenesulfonyl)-4H,5H-[l,2,3]triazolo[l,5- a]quinazolin-5-one (Compound 47);

3-(2,4-dimethylbenzenesulfonyl)-8-(l,4-oxazepan-4-yl)-4H,5H-[l,2,3]triazolo[l,5- a]quinazolin-5-one (Compound 48);

3-(2,4-dimethylbenzenesulfonyl)-8-[4-(2-methylpropanoyl)piperazin-l-yl]-4H,5H-

[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 52);

4-[3-(2,4-dimethylbenzenesulfonyl)-5-oxo-4H,5H-[l,2,3]triazolo[l,5-a]quinazolin-8- yl]-l-methylpiperazin-2-one (Compound 53);

3-(2,4-dimethylbenzenesulfonyl)-8-[4-(oxetan-3-yl)piperazin-l-yl]-4H,5H-

[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 55);

3-(2,4-dimethylbenzenesulfonyl)-8-[4-(oxan-4-yl)piperazin-l-yl]-lH,5H-

[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 56);

8-(4-cyclopropylpiperazin-l-yl)-3-(2,4-dimethylbenzenesulfonyl)-4H,5H-

[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 60);

3-(2,4-dimethylbenzenesulfonyl)-8-(4-methanesulfonylpiperazin-l-yl)-4H,5H-

[l,2,3]triazolo[l,5-a]quinazolin-5-one (Compound 61);

4-[3-(2,4-dimethylbenzenesulfonyl)-5-oxo-4H,5H-[l,2,3]triazolo[l,5-a]quinazolin-8- yl]piperazine-l -sulfonamide (Compound 62);

2-[3-(2,4-Dimethyl-benzenesulfonyl)-5-oxo-4,5-dihydro-[l,2,3]triazolo[l,5- a]quinazolin-8-yl]-2-aza-spiro[3.3]heptane-6-carboxylic acid (Compound 63); and l-[3-(2,4-Dimethyl-benzenesulfonyl)-5-oxo-4,5-dihydro-[l,2,3]triazolo[l,5- a]quinazolin-8-yl]-piperidine-4-carboxylic acid (Compound 64); or a pharmaceutically acceptable salt thereof.

14. A pharmaceutical composition comprising at least one compound according to any of the preceding claims, or a pharmaceutically acceptable salt, tautomer, solvate or hydrate thereof, and a pharmaceutically acceptable excipient.

15. A compound according to any of claims 1 to 13 or a pharmaceutically acceptable salt, tautomer, solvate or hydrate thereof, or a pharmaceutical composition according to claim 14, for use as a medicament.

Description:

8-HETEROCYCLIC-3-(PHENYLSULFONYL)-[1 ,2,3]TRIAZOLO[1 ,5A] QUINAZOLIN-5(4H)-ONE DERIVATIVES AS ANTI-BACTERIALS

The present invention relates to 8-heterocyclic-3-(phenylsulfonyl)-[l,2,3] triazolo[l,5a]quinazolin-5(4H)-one derivatives and pharmaceutical compositions thereof as well as to their uses in methods of reducing the virulence of bacteria (preferably Staphylococcus aureus) that express accessory gene regulator A (AgrA) or an ortholog of AgrA; in methods of inhibition of the quorum sensing in bacteria, preferably in S. aureus,' and in methods for preventing or treating diseases caused or exacerbated by bacteria, preferably by 5. aureus, such as skin or lung infections, atopic dermatitis, Netherton syndrome, or psoriasis in a subject. Thus, the present invention relates to anti-virulence compositions and methods for treatment, amelioration and/or prevention of diseases caused or exacerbated by bacteria, preferably by 5. aureus, and more particularly to compositions and methods for reducing the virulence of bacteria that express AgrA or an ortholog of AgrA, preferably AgrA.

RELATED ART

Staphylococcus aureus is both a human commensal and a notorious opportunistic pathogen causing serious community-acquired and hospital-acquired infections. 5. aureus is capable of causing a vast array of infections ranging from mild superficial skin infections to severe systemic life-threatening conditions such as endocarditis, pneumonia or sepsis (Lee AS, et al. (2018) Nat. Rev. Dis. Primers, Vol 4, Article 18033 pp. 1-23. Moreover, S. aureus has also been implicated in contributing to allergic skin conditions such as atopic dermatitis (Geoghegan JA, et al. (2018) Trends Microbiol. 26(6): 484-497) or Netherton syndrome (Williams MR, et al. (2020) Cell reports 30 (9): 2923-2933). The success of 5. aureus to cause such a variety of diseases is a consequence of the extensive arsenal of virulence factors produced combined with P-lactam resistance and, for most clones, resistance to other antibiotic classes. Clinically relevant antibiotic resistance has evolved against virtually every antibiotic deployed, while the discovery and development of novel antibiotic classes is lagging behind, provoking the antibiotic resistance crisis we are facing today. Consequently, alternative strategies to treat or prevent 5. oura/.s-mediated bacterial infections that are also efficacious against multidrug-resistant strains, such as the methicillin-resistant 5. aureus (MRSA), are needed (Dickey SW, et al. (2017) Nat. Rev. Drug Discov. 16(7):457-471).

One of these strategies is the anti-virulence approach by which only virulence- associated, but not survival/fitness-relevant traits are targeted. In contrast to common antibiotic therapies, anti- virulence drugs are not per se bacteriostatic (inhibiting bacterial growth) or bactericidal (killing bacteria). This approach focuses on disarming the pathogenic bacteria by blocking the expression or neutralizing their virulence factors, ultimately interfering with bacterial pathogenicity mechanisms and thereby promoting pathogen clearance by the host immune system. Because anti-virulence drugs do not interfere with essential mechanisms of bacterial growth and survival, they are supposed to alleviate the pressure on the pathogen to develop resistance. A further advantage is that specific anti- virulence drugs preserve the healthy host microbiota, and eventually even help to counteract microbial dysbiosis by tuning down the aggressiveness of pathogens such as 5. aureus. Importantly, anti-virulence approaches offer an increased repository of pharmacological targets, and thus the possibility of generating alternative antimicrobials with novel mode of action (Muhlen, S. & Dersch, P. (2016) Curr. Top. Microbiol. Immunol. 398:147-183).

How the virulence factors are regulated in 5. aureus'. The agr operon is a bacterial quorum-sensing system that controls cell-density dependent virulence factor expression in 5. aureus. It consists of two divergent promoters, P2 and P3, where P2 is responsible for producing the components of the quorum-sensing system (AgrB, AgrD, AgrC, and AgrA; see FIG 1). The precursor peptide AgrD is processed by AgrB to form the mature auto-inducing peptide (AIP) that is secreted across the bacterial membrane. AIP binds to the histidine-kinase AgrC and activates the transcriptional regulator AgrA by means of phosphorylation, driving the expression from P2 and P3. There are four allelic variants (types I-IV) of agr, each encoding a distinct AIP, which functions as specific ligand for the AgrC of its own cell, but as an inhibitor of other AgrC variants. P3 produces the agr effector molecule RNAIII that together with AgrA is responsible for transcriptional control of approximately 200 genes including multiple virulence factors and metabolic pathways involved in stationary phase growth (Khan, BA, et al. (2015) Expert Opin. Investig. Drugs 24(5):689-704). Examples for AgrA-regulated virulence factors are cell-surface associated proteins, such as protein A (SpA) and fibronectin- binding proteins, secreted toxins such as a-hemolysin/a-toxin (Hla), 8-hemolysin (Hid), phenol-soluble-modulins (PSMs), Panton-Valentine leukocidin (PVL), leukotoxin E and D (LukED), leukotoxin G and H (LukGH), or secreted proteases such as SspA or aureolysin. Taken together, the numerous and multi-functional virulence determinants make S. aureus pathogenesis particularly complex and provide the pathogen with an arsenal of mechanisms to damage the host or circumvent and evade the host immune defenses. Important to note, most AgrA-regulated virulence factors are causative for the S. aureus pathogenicity in skin and soft tissue infections (SSTIs), lung infections, and were also shown to contribute to chronic inflammatory skin diseases, such as atopic dermatitis (Oliveira D. etal. (2018) Tox/tis 10: 252; Geoghegan JA, et al. (2018) Trends Microbiol. 26(6): 484-497) and Netherton syndrome (Williams MR, et al. (2020) Cell reports 30 (9): 2923-2933).

How to prevent virulence factor expression: Inhibition of expression of the central regulatory RNAIII combined with inhibition of PSMa production is believed to lead to apotent global reduction in levels of virulence factors (see FIG 1). Current strategies to suppress RNAIII expression can be grouped into different categories: (1) competitive inhibitors of histidine kinase AgrC; (2) RNAIII transcription inhibitors (precise mechanisms undetermined); and (3) inhibition of AgrA-P2/Ps interactions. Targeting AgrA has the advantage of blocking AgrA- d ependent virulence factor expression on all four agr groups (Gordon CP, et al. (2013) J. Med. Chem. 56(4): 1389-404).

An AgrA inhibitor termed Savirin was found by Sully and colleagues in a screen of 24’087 compounds selected for inhibition of cyclic thiolactone peptide pheromone (AIP)- induced agr in the context of studies related to acute bacterial skin and soft tissue infections caused by S. aureus (Sully EK, etal. (2014) PLoS Pathog. 10(6): el004174). Savirin was shown to be a potent modulator of AgrA-regulated toxin gene transcription such as hla, psmaand pvl across all four agr groups without affecting viability of 5. aureus. Savirin inhibited exotoxin- induced red blood cell (RBC) lysis. No resistance was developed after multiple passages with Savirin. The molecule was shown to interfere with the AgrA-DNA interaction, preventing virulence gene upregulation. A significant reduction in abscess size and dermonecrosis was observed in mice infected with a MRSA USA300 type strain when Savirin was applied multiple times.

Recently, WO 2020/109350 described 3-(phenylsulfonyl)-[l,2,3]triazolo[l,5a]quina- zolin-5(4h)-one derivatives that are capable of reducing the virulence of bacteria such as 5. aureus by interacting with AgrA and inhibiting the expression of AgrA-regulated virulence factors, and its uses for preventing or treating bacterial infections and/or diseases caused or exacerbated by bacteria, preferably by 5. aureus, such as skin or lung infections, atopic dermatitis or psoriasis.

SUMMARY OF THE INVENTION

The inventors have surprisingly found that the ability to inhibit AgrA-related virulence factors by compounds of WO 2020/109350 could be affected and reduced when tested in the presence of human serum (HS) or human serum albumin (HSA; the major component of human serum). Without wishing to be bound, the reduced ability to inhibit expression of AgrA-related virulence factors is thought to be due to nonspecific binding of the compounds to serum proteins (e.g., HSA). Such reduced efficacy in the presence of HS or HSA can limit the ability to inhibit AgrA-related virulence factors when administered systemically (e.g., in an animal, preferably a mammal, more preferably a human). The present invention now provides a new class of compounds overcoming said drawbacks, and thus provides compounds that can reduce the virulence of bacteria, preferably that express AgrA and/or inhibit quorum sensing in bacteria, preferably in 5. aureus, in biologically relevant systems that include human serum or human serum albumin.

Thus, the inventors have surprisingly identified a new class of compounds able to interact with AgrA and inhibit the expression of AgrA-regulated virulence factors even in the presence of human serum (HS) or human serum albumin (HSA). The inventors transfected 5. aureus with a plasmid expressing the reporter gene lacZ under the control of the Ps promoter, which is regulated by AgrA. In the presence of the inventive compounds, the inventors found that production of the gene product of lacZ (i.e., B-galactosidase) was inhibited. Surprisingly, the inventive compounds retained AgrA inhibition activity even when the assay was performed in the presence of HS or HSA.

The inventive compounds can thus inhibit the transcription of genes (preferably virulence factors) under the control of the Ps promoter (e.g., in bacteria, preferably in 5. aureus) in the presence of HS or HSA. This activity strongly suggests that the inventive compounds can be administered systemically (e.g., orally or parenterally) in biologically relevant systems (e.g., in animals, preferably mammals, more preferably humans) while still maintaining efficacy. Additional features and advantages of the present technology will be understood by those of skill in the art upon reading the Detailed Description of the Invention, below.

In a first aspect, the present disclosure provides a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, or tautomer thereof: Formula (I) wherein:

R ¹ is independently selected from -H, halogen, -Ci-Ce alkyl, and -Ci-Ce alkoxy, wherein said alkyl and alkoxy is each optionally substituted with one or more R ¹¹;

R ³ is independently selected from -H, -Ci-Ce alkyl, and -Ci-Ce alkoxy, wherein said alkyl and alkoxy is each optionally substituted by one or more R ¹¹;

R ⁷ is independently selected from -H and -OH;

R ⁸ is a group of the Formula (A): Formula (A) wherein n is independently an integer from 0 to 3; m is independently an integer from 0 to 3;

Y ¹ is independently, at each occurrence, selected from CR ⁸¹R ⁸², C(O), and O;

Y ² is independently, at each occurrence, selected from CR ^81AR ^82A, and O;

Y ³ is independently selected from CR ⁸⁴R ⁸⁵; CHR ⁸⁶; NR ⁸⁷, and O; wherein the sum of m and n is at least 2 when Y ³ is CR ⁸⁴R ⁸⁵ and wherein the sum of m and n is at least 3 when Y ³ is CHR ⁸⁶, NR ⁸⁷, or O;

R ⁸¹, R ⁸², R ^81A and R ^82A are independently, at each occurrence, selected from -H and - Ci-Ce alkyl, or one of R ⁸¹ and R ^81A, together with the carbon atoms to which they are attached, can combine to form a bridging ethylene;

R ⁸⁴ and R ⁸⁵, together with the carbon atom to which they are attached, combine to form a -C4-C7 cycloalkyl or a 4- to 7- membered heterocycle, wherein said cycloalkyl and heterocycle is each optionally substituted with one or more halogen, -Ci-Ce alkyl, -Ci-Ce haloalkyl, -OH, or -COOH;

R ⁸⁶ is independently selected from -H, -COOH, and -NR ⁸⁸R ⁸⁹; or R ⁸⁶, together with the carbon atom to which it is attached, can combine with one of R ⁸¹, R ^81A, R ⁸² or R ^82A and the carbon atoms to which they are attached to form a 5- to 6-membered heterocycle, wherein said heterocycle is optionally substituted with one or more halogen, -Ci-Ce alkyl, -Ci-Ce haloalkyl, or -OH;

R ⁸⁸ and R ⁸⁹ are independently, at each occurrence, selected from -H and -Ci-Ce alkyl, or one of R ⁸⁸ or R ⁸⁹, together with the nitrogen atom to which they are attached, can combine with one of R ⁸¹, R ^81A, R ⁸² or R ^82A and the carbon atoms to which they are attached to form a 5- to 6-membered heterocycle;

R ⁸⁷ is independently selected from -H, -Ci-Ce alkyl, -C(O)Ci-Ce alkyl, -S(O)2NH2, - S(O)2Ci-Ce alkyl, -Cs-Ce cycloalkyl, and 4- to 6-membered heterocycle; wherein each alkyl is optionally substituted with one or more halogen, -Ci-Ce alkoxy, -OH, -O(CH2)2-OH, -NH2, - NHCi-Ce alkyl, or N(Ci-Ce alkyl)2; wherein said cycloalkyl is optionally substituted with one or more halogen, -Ci-Ce alkyl, -Ci-Ce haloalkyl, or -OH; wherein said heterocycle is optionally substituted with one or more halogen, -Ci-Ce alkyl, -Ci-Ce haloalkyl, or -OH; or R ⁸⁷, together with the nitrogen atom to which it is attached, can combine with one of R ⁸¹, R ^81A, R ⁸² or R ^82A and the carbon atoms to which they are attached to form a 5- to 6- membered heterocycle or 5- to 6-membered heteroaryl, wherein said heterocycle or heteroaryl is each optionally substituted with one or more halogen, -Ci-Ce alkyl, -Ci-Ce haloalkyl, or -OH; and

R ¹¹ is independently, at each occurrence, halogen or -OH.

In one aspect, the present disclosure provides a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, or tautomer thereof: Formula (I) wherein:

R ¹ is independently selected from -H, halogen, -Ci-Ce alkyl, and -Ci-Ce alkoxy, wherein said alkyl and alkoxy is each optionally substituted with one or more R ¹¹;

R ³ is independently selected from -H, -Ci-Ce alkyl, and -Ci-Ce alkoxy, wherein said alkyl and alkoxy is each optionally substituted by one or more R ¹¹;

R ⁷ is independently selected from -H and -OH;

R ⁸ is a group of the Formula (A): Formula (A) wherein n is independently an integer from 0 to 3; m is independently an integer from 0 to 3;

Y ¹ is independently, at each occurrence, selected from CR ⁸¹R ⁸², C(O), and O;

Y ² is independently, at each occurrence, selected from CR ^81AR ^82A, and O;

Y ³ is independently selected from CR ⁸⁴R ⁸⁵; CHR ⁸⁶; NR ⁸⁷, and O; wherein the sum of m and n is at least 2 when Y ³ is CR ⁸⁴R ⁸⁵ and wherein the sum of m and n is at least 3 when Y ³ is CHR ⁸⁶, NR ⁸⁷, or O;

R ⁸¹, R ⁸², R ^81A and R ^82A are independently, at each occurrence, selected from -H and - Ci-Ce alkyl, or one of R ⁸¹ and R ^81A, together with the carbon atoms to which they are attached, can combine to form a bridging ethylene;

R ⁸⁴ and R ⁸⁵, together with the carbon atom to which they are attached, combine to form a -C4-C7 cycloalkyl or a 4- to 7- membered heterocycle, wherein said cycloalkyl and heterocycle is each optionally substituted with one or more halogen, -Ci-Ce alkyl, -Ci-Ce haloalkyl, or -OH;

R ⁸⁶ is independently selected from -H, and -NR ⁸⁸R ⁸⁹; or R ⁸⁶, together with the carbon atom to which it is attached, can combine with one of R ⁸¹, R ^81A, R ⁸² or R ^82A and the carbon atoms to which they are attached to form a 5- to 6-membered heterocycle, wherein said heterocycle is optionally substituted with one or more halogen, -Ci-Ce alkyl, -Ci-Ce haloalkyl, or -OH;

R ⁸⁸ and R ⁸⁹ are independently, at each occurrence, selected from -H and -Ci-Ce alkyl, or one of R ⁸⁸ or R ⁸⁹, together with the nitrogen atom to which they are attached, can combine with one of R ⁸¹, R ^81A, R ⁸² or R ^82A and the carbon atoms to which they are attached to form a 5- to 6-membered heterocycle;

R ⁸⁷ is independently selected from -H, -Ci-Ce alkyl, -C(O)Ci-Ce alkyl, -S(O)2NH2, - S(O) ₂Ci-C ₆ alkyl, -Cs-Ce cycloalkyl, and 4- to 6-membered heterocycle; wherein each alkyl is optionally substituted with one or more halogen, -Ci-Ce alkoxy, -OH, -O(CH2)2-OH, -NH2, - NHCi-Ce alkyl, or N(Ci-Ce alkyl)2; wherein said cycloalkyl is optionally substituted with one or more halogen, -Ci-Ce alkyl, -Ci-Ce haloalkyl, or -OH; wherein said heterocycle is optionally substituted with one or more halogen, -Ci-Ce alkyl, -Ci-Ce haloalkyl, or -OH; or R ⁸⁷, together with the nitrogen atom to which it is attached, can combine with one of R ⁸¹, R ^81A, R ⁸² or R ^82A and the carbon atoms to which they are attached to form a 5- to 6- membered heterocycle or 5- to 6-membered heteroaryl, wherein said heterocycle or heteroaryl is each optionally substituted with one or more halogen, -Ci-Ce alkyl, -Ci-Ce haloalkyl, or -OH; and

R ¹¹ is independently, at each occurrence, halogen or -OH.

In one aspect, the invention provides an inventive compound as described herein or a pharmaceutical composition comprising an inventive compound as described herein for use in a method of reducing the virulence of a bacteria, preferably wherein the bacteria is of a genus selected from Staphylococcus, Streptococcus or Clostridium, more preferably of Staphylococcus, and again further preferably is Staphylococcus aureus, preferably wherein the bacteria expresses AgrA or an ortholog of AgrA, more preferably wherein the bacteria expresses AgrA.

In one aspect, the invention provides an inventive compound as described herein or a pharmaceutical composition comprising an inventive compound as described herein for use in a method of inhibiting the quorum sensing in bacteria, preferably wherein the bacteria is of a genus selected from Staphylococcus, Streptococcus or Clostridium, more preferably of Staphylococcus, and again further preferably is Staphylococcus aureus, preferably wherein the bacteria expresses AgrA or an ortholog of AgrA, more preferably wherein the bacteria expresses AgrA.

In one aspect, the invention provides an inventive compound as described herein or a pharmaceutical composition comprising an inventive compound as described herein for use in a method of preventing or treating diseases caused or exacerbated by bacteria, preferably a bacteria of a genus selected from Staphylococcus, Streptococcus or Clostridium, more preferably of Staphylococcus, and again further preferably is Staphylococcus aureus, preferably wherein the disease is a skin disease or a lung disease, more preferably wherein the skin disease is atopic dermatitis, Netherton syndrome, or psoriasis.

In one aspect, the present disclosure provides a pharmaceutical composition comprising at least one compound according to Formula (I), or a pharmaceutically acceptable salt, tautomer, solvate or hydrate thereof, and a pharmaceutically acceptable excipient.

In one aspect, the present disclosure provides a compound according to Formula (I) or a pharmaceutically acceptable salt, tautomer, solvate or hydrate thereof, or a pharmaceutical composition comprising a compound according to Formula (I), for use as a medicament.

DESCRIPTION OF THE FIGURES

FIG 1 shows quorum sensing signaling in staphylococci to control virulence factor production. The precursor peptide AgrD is processed by AgrB and the mature auto-inducing peptide (AIP) is secreted across the bacterial membrane. AIP binds to the histidine-kinase AgrC of its own cell or on other bacterial cells. AgrC then activates response regulator AgrA by means of phosphorylation. Phospho-AgrA binds to and activates transcription from the agr P2 and P3 promoters, as well as the promoters of the psm operons (RNAIII-independent AgrA regulation). The classic targets of AgrA are under RNAIII-dependent control, comprising several toxins and proteases that are up-regulated and several surface-binding proteins such as protein A, that are down-regulated. Small molecule inhibitors that bind to the DNA-binding domain of AgrA prevent the binding to P2 and P3 promoter, thus blocking continuous production of AIP (P2 driven) and virulence factors (P3 driven) but also block expression of RNAIII-independent AgrA regulation such as production of PSMs.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to compounds and pharmaceutical compositions comprising the same that can inhibit the transcription of genes under the control of the P3 promoter (e.g., in bacteria, preferably in 5. aureus) even in the presence of HS or HSA.

Definitions

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. The herein described and disclosed embodiments, preferred embodiments and very preferred embodiments should apply to all aspects and other embodiments, preferred embodiments and very preferred embodiments irrespective of whether is specifically again referred to or its repetition is avoided for the sake of conciseness.

The articles “a” and “an” are used in this disclosure to refer to one or more than one (i.e., to at least one) of the grammatical object of the article unless the context clearly dictates otherwise. By way of example, “an element” means one element or more than one element.

The term “and/or” is used in this disclosure to mean either “and” or “or” unless indicated otherwise.

The term “optionally substituted” is understood to mean that a given chemical moiety (e.g. an alkyl group) can (but is not required to) be bonded other substituents (e.g. heteroatoms). For instance, an alkyl group that is optionally substituted can be a fully saturated alkyl chain (i.e. a pure hydrocarbon). Alternatively, the same optionally substituted alkyl group can have substituents different from hydrogen. For instance, it can, at any point along the chain be bounded to a halogen atom, a hydroxyl group, or any other substituent described herein. Thus, the term “optionally substituted” means that a given chemical moiety has the potential to contain other functional groups, but does not necessarily have any further functional groups.

The term “alkyl” refers to a straight or branched chain saturated hydrocarbon. Ci-Ce alkyl groups contain 1 to 6 carbon atoms. Examples of a-Ci-Ce alkyl group include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, isopropyl, isobutyl, sec-butyl and tert-butyl, isopentyl and neopentyl.

The term “cycloalkyl” means monocyclic saturated carbon ring containing 3-7 carbon atoms. Examples of cycloalkyl groups include, without limitations, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.

Unless otherwise specifically defined, “heteroaryl” means a monovalent monocyclic aromatic radical of 5 to 6 ring atoms containing one or more ring heteroatoms selected from N, S, P, and O, the remaining ring atoms being C. Preferably the heteroatom is selected from N, S, and O, more preferably N and O. The aromatic radical is optionally substituted independently with one or more substituents described herein. Examples include, but are not limited to, furyl, thienyl, pyrrolyl, pyridyl, pyrazolyl, pyrimidinyl, imidazolyl, isoxazolyl, oxazolyl, oxadiazolyl, and pyrazinyl. The heteroaryl group can be fused to a partially saturated heterocycle, e.g., as in Compound 54. Additional exemplary ring systems of such heterocyle-aryl or heterocyle- heteroaryl groups include indolinyl, indolinonyl, dihydrobenzothiophenyl, dihydrobenzofuran, chromanyl, thiochromanyl, tetrahydroquinolinyl, dihydrobenzothiazine, 3,4-dihydro-lH— isoquinolinyl, 2,3-dihydrobenzofuran, 2,3,4,5-tetrahydro-lH-pyrido[4,3-b]indole, 5, 6,7,8- tetrahydro-imidazo[l,2-a]pyrazine, and dihydrobenzoxanyl.

The terms “heterocyclyl” or “heterocycloalkyl” or “heterocycle” refer to monocyclic or bicyclic saturated or partially saturated 4 to 11 -membered rings containing carbon and heteroatoms taken from O, N, and S (preferably O and N) and wherein the ring or rings do not comprise delocalized n electrons (aromaticity) shared among the ring carbons or heteroatoms. Heterocyclyl rings include, but are not limited to, oxetanyl, azetadinyl, tetrahydrofuranyl, pyrrolidinyl, oxazolinyl, oxazolidinyl, thiazolinyl, thiazolidinyl, pyranyl, thiopyranyl, tetrahydropyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, [1,4] diazepane, and [1,2] diazepane. A heterocyclyl or heterocycloalkyl ring can be bridged, e.g., as shown in Compound 50.

As shown in Compounds 3-21, when Y ³ is CR ⁸⁴R ⁸⁵, R ⁸ forms a spirocyclic heterocycle with the ring of Formula (A). As used herein a spirocyclic heterocycle or spiroheterocycle is understood to mean a bicyclic ring system in which both rings are connected through a single atom, and wherein at least one of the rings is a heterocycle (e.g., at least one of the rings is azetidine, pyrrolidine, morpholine, or piperidine).

As used herein, the term “halo” or “halogen” means fluoro (F), chloro (Cl), bromo (Br), or iodo (I).

The term “oxo” refers to a carbonyl functional group composing a carbon atom doublebonded to an oxygen atom. It can be abbreviated herein as “oxo”, as C(O), or as C=O.

The invention also includes pharmaceutical compositions comprising an effective amount of a disclosed compound and a pharmaceutically acceptable carrier. The terms “pharmaceutically acceptable” or “therapeutically acceptable” refers to a substance which does not interfere with the effectiveness or the biological activity of the active ingredients and which is not toxic to the host. Representative “pharmaceutically acceptable salts” include, e.g., water- soluble and water-insoluble salts, such as the acetate, amsonate (4,4-diaminostilbene-2,2- disulfonate), benzenesulfonate, benzonate, bicarbonate, bisulfate, bitartrate, borate, bromide, butyrate, calcium, calcium edetate, camsylate, carbonate, chloride, citrate, clavulariate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexafluorophosphate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, hydroiodide, sethionate, lactate, lactobionate, laurate, magnesium, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, N-methylglucamine ammonium salt, 3-hydroxy-2-naphthoate, oleate, oxalate, palmitate, pamoate (l,l-methene-bis-2-hydroxy-3- naphthoate, einbonate), pantothenate, phosphate/diphosphate, picrate, poly galacturonate, propionate, p-toluenesulfonate, salicylate, stearate, subacetate, succinate, sulfate, sulfosalicylate, suramate, tannate, tartrate, teoclate, tosylate, triethiodide, and valerate salts.

The term “tautomers” refers to a set of compounds that have the same number and type of atoms, but differ in bond connectivity and are in equilibrium with one another. A “tautomer” is a single member of this set of compounds. Typically, a single tautomer is drawn but it is understood that this single structure is meant to represent all possible tautomers that might exist. Examples include enol-ketone tautomerism. When a ketone is drawn it is understood that both the enol and ketone forms are part of the present disclosure.

The term “solvate” refers to a complex of variable stoichiometry formed by a solute and solvent. Such solvents for the purpose of the invention may not interfere with the biological activity of the solute. Examples of suitable solvents include, but are not limited to, water, MeOH, EtOH, and AcOH. Solvates wherein water is the solvent molecule are typically referred to as “hydrates.” Hydrates include compositions containing stoichiometric amounts of water, as well as compositions containing variable amounts of water.

The term “carrier”, as used in this disclosure, encompasses carriers, excipients, and diluents and means a material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting a pharmaceutical agent from one organ, or portion of the body, to another organ, or portion of the body of a subject.

The term “disorder” is used in this disclosure to mean, and is used interchangeably with, the terms disease, condition, or illness, unless otherwise indicated.

The term “administer”, “administering”, or “administration” as used in this disclosure refers to either directly administering a disclosed compound or pharmaceutically acceptable salt of the disclosed compound or a composition to a subject, or administering a prodrug derivative or analog of the compound or pharmaceutically acceptable salt of the compound or composition to the subject, which can form an equivalent amount of active compound within the subject's body.

The term “ortholog”, as used herein, denotes the well-known meaning of this term. In this art, orthologs are genes in different species which evolved from a common ancestral gene. Due to their separation following a speciation event, orthologs may diverge, but usually have similarity at the sequence and structure levels; furthermore, orthologs usually have identical functions. Orthology is a type of homology. In this application, the term ortholog is used to include the ortholog gene (DNA or RNA) or the peptide/protein product of the ortholog. Sometimes the peptide/protein product of the ortholog is referred to as “ortholog product' or simply "ortholog”. The meaning is evident from the context (e.g., an anti-virulence compositions of the present invention may include an anti- virulence agent capable of reducing the virulence of bacterium that expresses peptides or proteins that may be referred to as orthologs of AgrA - that is, products of an ortholog gene of Staphylococcus aureus AgrA from another bacterium, such as Streptococcus pyogenes). In certain aspects, an ortholog of AgrA produces proteins/peptides that share greater than about 70%, about 80%, or about 90% identity with the amino acid sequence of the gene product of AgrA.

The terms “reducing” and “inhibiting” have their commonly understood meaning of lessening or decreasing.

The expression “reducing the virulence of bacteria that express AgrA”, as used herein, typically and preferably, refers to inhibiting the synthesis of one or more virulence factors by said bacteria by the inventive compounds of formula (I) or the inventive compositions, preferably pharmaceutical compositions, comprising an inventive compound of formula (I). Examples for AgrA-regulated virulence factors are cell-surface associated proteins, such as protein A (SpA) and fibronectin-binding proteins, secreted toxins such as a-hemolysin/a-toxin (Hla), 8-hemolysin (Hid), phenol-soluble-modulins (PSMs), Panton-Valentine leukocidin (PVL), leukotoxin E and D (LukED), leukotoxin G and H (LukGH) or secreted proteases such as SspA or aureolysin. In a preferred example and embodiment of the present invention, said reducing the virulence of bacteria that express AgrA is inhibiting the synthesis of one or more virulence factor selected from PSMa, RNAIII and its downstream targets. In a preferred example and embodiment of the present invention, said reducing the virulence of bacteria that express AgrA is inhibiting the synthesis of PSMa. In a preferred example and embodiment of the present invention, said reducing the virulence of bacteria that express AgrA is inhibiting the synthesis of RNAIII and/or its downstream targets, preferably of RNAIII.

The term “inhibiting the synthesis of one or more virulence factors” as used herein shall refer to a complete or partial inhibition (preferably more than 20%, further preferably more than 30%, further preferably more than 50%, further preferably more than 90%, still more preferably more than 95% or even more than 99%) of the synthesis of one or more virulence factors, as compared to the synthesis of one or more virulence factors by said bacteria in the absence of the inventive compounds of formula (I) or the inventive compositions, preferably pharmaceutical compositions, comprising an inventive compound of formula (I) or as compared to an inventive method where no such inventive compounds of formula (I) or the inventive compositions, preferably pharmaceutical compositions, comprising an inventive compound of formula (I) are applied or used.

Virulence factors as contemplated herein include any molecules expressed and secreted by bacteria to promote colonization and/or adhesion in a host subject, promote inflammation in the host tissue, promote evasion of the host’s immune response and obtain nutrition from the host subject. Virulence factors can also include both exotoxins and endotoxins. Non-limiting examples of virulence factors inhibited by an inventive compound of formula (I) or an inventive composition, preferably an inventive pharmaceutical composition, comprising an inventive compound of formula (I), as described herein, include one or more of toxins (e.g., a, p, y, y- variant, and 8-hemolysins, PSMs (e.g., PSMa), Panton-Valentine leukocidin (PVL), leukotoxin E and D (LukED), leukotoxin G and H (LukGH), enterotoxins (e.g., enterotoxin B), exfoliative toxin), proteases (e.g., serine proteases, metalloproteases and cysteine proteases), nuclease, lipase, coagulase, hyaluronidase, fibronectin-binding protein, clumping factor, pyrogenic toxin superantigen (e.g., TSST-1). In a preferred embodiment, the virulence factor inhibited is RNAIII and/or its downstream targets or PSMa.

Depending on the severity of the infection or if used in a preventive manner, the antivirulence drugs can be administered alone or in combination with therapeutic agents such as antibiotics typically and preferably used for prevention and treatment of infections caused by bacteria such as Staphylococcus, primarily by Staphylococcus aureus (e.g., pneumonia, blood stream infections, acute skin and skin structure infections).

The anti-virulence drugs can be administered alone or in combination with therapeutic agents typically and preferably used for prevention and treatment of chronic inflammatory skin disease (e.g., atopic dermatitis, Netherton syndrome, psoriasis) which are exacerbated by bacteria such as Staphylococcus, primarily by Staphylococcus aureus.

The term “antibiotic”, as used herein, refers to an antimicrobial agent or anti-infective that kills bacteria (bactericidal antibiotics) or inhibits growth and/or metabolism of bacteria (bacteriostatic antibiotics). Antibiotics are well-known to the skilled person in the art, and specific and preferred examples thereof include penicillins, cephalosporins, polymyxins, rifamycins, lipiarmycins, quinolones, sulfonamides, macrolides, oxazolidinones, lincosamides and tetracyclines.

The term "treating", “treatment” or "therapy" as used herein refers to means of obtaining a desired physiological effect. The effect may be therapeutic in terms of partially or completely curing a disease or a condition and/or symptoms attributed to the disease or the condition. The term refers to inhibiting the disease or condition, i.e. arresting its development; or ameliorating the disease or condition, i.e. causing regression of the disease or condition.

The term "prevention" as used herein refers to means of preventing or delaying the onset of disease or condition and/or symptoms attributed to the disease or condition.

As used herein, the terms "subject" or "animal" or "patient" or "mammal," refers to any subject, particularly a mammalian subject, for whom diagnosis, prognosis, prophylaxis or therapy is desired, for example, a human or a domesticated mammal such as a dog, cat or horse or a food animal such as a cow or sheep or pig, preferably to a human. Thus, in a preferred embodiment of the present invention, said subject is a human.

As used herein, the term "for use" as used in "composition for use in treatment or prevention of a disease” shall disclose also the corresponding method of treatment or prevention and the corresponding use of a preparation for the manufacture of a medicament for the treatment or prevention of a disease".

A "therapeutically effective amount" or "effective amount" is the amount of a compound or pharmaceutical composition in accordance with the present invention that will elicit the biological or medical response of a subject, preferably a human subject that is being sought by the researcher, veterinarian, medical doctor or other clinician. The term “therapeutic administration”, as used herein, should refer to the administration of therapeutically effective amount. In particular, the terms “effective”, “effective amount”, and “therapeutically effective amount”, as used herein, typically and preferably, refer to that amount of an inventive compounds of formula (I) or an inventive composition, preferably an inventive pharmaceutical composition, comprising an inventive compound of formula (I) that reduces the virulence of a bacterium or that results in amelioration of symptoms or a prolongation of survival in a subject with a bacteria related disease or disorder. The term "effective amount" is used generically herein to refer to the amount of a given compound or in case of a mixture the combined amount of mixture components that provides a measurable effect for a listed function. It will be understood by one of ordinary skill in the art, that for a given application, the effective amount can be determined by application of routine experimentation and without undue experimentation by methods that are described herein or that are known in the art. The term "therapeutically effective amount" is used generically herein to refer to the amount of a given compound or in case of a mixture the combined amount of mixture components when administered to the individual including a human or non-human animal, that provides a measurable therapeutic effect for a listed disease, disorder or condition to at least partially ameliorate a symptom of such disease, disorder or condition. The result of treatment can be partially or completely alleviating, inhibiting, preventing, ameliorating and/or relieving the disorder, condition or one or more symptoms thereof. Compounds of the invention